skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current and emerging therapies for the treatment of osteoporosis

Review

(1988) Views  (870) Full article downloads

Authors: Jill Waalen

Published Date August 2010 Volume 2010:2 Pages 121 - 134
DOI: http://dx.doi.org/10.2147/JEP.S7823

Jill Waalen
Department of Molecular and Experimental Medicine, The Scripps Research Institute, CA, USA

Abstract: Osteoporosis represents a weakening of bone tissue due to an imbalance in the dynamic processes of bone formation and bone resorption that are continually ongoing within bone tissue. Most currently available osteoporosis therapies are antiresorptive agents. Over the past decade, bisphosphonates, notably alendronate and risedronate, have become the dominant agents with newer bisphosphonates such as ibandronate and zoledronic acid following a trend of less frequent dosing regimens. Synthetic estrogen receptor modulators (SERMs) continue to be developed as drugs that maintain the bone-protective effects of estrogen while avoiding its associated adverse side effects. Currently available agents of this class include raloxifene, the only SERM available in the United States (US), and lasofoxifene and bazedoxifene, available in Europe. Calcitonin, usually administered as a nasal spray, completes the list of currently approved antiresorptive agents, while parathyroid hormone analogs represent the only anabolic agents currently approved in both the US and Europe. Strontium ranelate is an additional agent available in Europe but not the US that has both anabolic and antiresorptive activity. New agents expected to further expand therapeutic options include denosumab, a monoclonal antibody inhibitor of the resorptive enzyme cathepsin K, which is in the final stages of Food and Drug Administration approval. Other agents in preclinical development include those targeting specific molecules of the Wnt/β-catenin pathway involved in stimulating bone formation by osteoblast cells. This review discusses the use of currently available agents as well as highlighting emerging agents expected to bring significant changes to the approach to osteoporosis therapy in the near future.

Keywords: bone formation, bone resorption, antiresorptive agent, anabolic agent








Readers of this article also read:

Update on bazedoxifene: A novel selective estrogen receptor modulator
Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
Potential antidiabetic and antioxidant activities of Morus indica and Asystasia gangetica in alloxan-induced diabetes mellitus
Pharmacological modulation of brain levels of glutamate and GABA in rats exposed to total sleep deprivation
The warfarin–cranberry juice interaction revisited: A systematic in vitro–in vivo evaluation
Clinical utility of denosumab for treatment of bone loss in men and women
Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates
Hibiscus sabdariffa L., roselle calyx, from ethnobotany to pharmacology
Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University